Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.39 |
| ▸ | MAPT | P10636 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15081397 | 0.90 | ALDH1A1 (0.41) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL14909672 | 0.89 | ALDH1A1 (0.40) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL14928321 | 0.83 | CYP19A1 (0.38) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL16168982 | 0.83 | MAPT (0.39) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL14928604 | 0.79 | TDO2 (0.39) | ALDH1A1MAPTMEN1KMT2ANPC1 | |
| SCHEMBL14910391 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL3387868 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL3348589 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL14928362 | 0.74 | MAPT (0.48) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL14928319 | 0.74 | MAPT (0.43) | ALDH1A1MAPTMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | ALDH1A1 1638/4885MAPT 4186/4885MEN1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.